Safety of Anlotinib Capsules Combined with PD-1 Inhibitor Camrelizumab in the Third-Line Treatment of Advanced Non-Small-Cell Lung Cancer and Their Effect on Serum Tumor Markers

OBJECTIVE: To explore the safety of anlotinib capsules combined with the PD-1 inhibitor (camrelizumab) in the third-line treatment of advanced non-small-cell lung cancer (NSCLC) and their effect on serum tumor markers. METHODS: 88 patients with advanced NSCLC treated in the Oncology Department of ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yinhua, Shi, Xiuhua, Qi, Qinghua, Ye, Bin, Zou, Zhaoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694967/
https://www.ncbi.nlm.nih.gov/pubmed/34956561
http://dx.doi.org/10.1155/2021/2338800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694967/
https://www.ncbi.nlm.nih.gov/pubmed/34956561
http://dx.doi.org/10.1155/2021/2338800

Ejemplares similares